GSK commences Phase III clinical trials to develop herpes zoster vaccine for the prevention of shingles

25-Aug-2010 - United Kingdom

GlaxoSmithKline confirmed that the company has commenced the Phase III clinical trials programme of its candidate herpes zoster vaccine currently being developed for the prevention of shingles. The phase III clinical trials will study more than 30,000 patients globally and will evaluate the efficacy, safety and immunogenicity of the candidate vaccine.

‘The commencement of the Phase III programme for our candidate herpes zoster vaccine is a significant milestone’, said Norman Begg, Chief Medical Officer of GSK Biologicals. ‘Shingles is an often debilitating condition for which there are limited treatment and prevention options. That is why progression into late stage development of our herpes zoster vaccine is an important milestone in ongoing efforts to potentially help address an important unmet need’.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances